Here you can find news from MPG spin-off companies.
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1
Evotec and venture capital consortium form Breakpoint Therapeutics GmbH
Evotec completes acquisition of Just Biotherapeutics
MorphoSys's Licensing Partner GSK Initiates Phase 3 Clinical Program With Otilimab (MOR103/GSK3196165) in Rheumatoid Arthritis; MorphoSys Updates its Financial Guidance for 2019